Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06848231 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
A Phase 2 study of Multiple System Atrophy, sponsored by Yoda Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 9
- Study locations
NCT06848231: Recruiting Phase 2 study of Multiple System Atrophy, sponsored by Yoda Therapeutics.
NCT06848231 is a Phase 2 study of Multiple System Atrophy that is actively recruiting participants, run by Yoda Therapeutics. The registered enrollment target is 75 participants, below the 266-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (72% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06848231, a Phase 2 study of Multiple System Atrophy, is actively recruiting participants, sponsored by Yoda Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
Primary Outcome
Incidence and severity of Adverse Events (AEs).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG YA-101
Study Locations (9)
Other
- Juntendo University Hospital - Tokyo
- National Taiwan University Hospital - Taipei
- National Taiwan University Hospital Cancer Center - Taipei
California
- UCLA Health - Los Angeles
Massachusetts
- Brigham and Women's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
New York
- Columbia University Irving medical center - New York
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT06848231 shows while recruiting
NCT06848231 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 266-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Multiple System Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06848231 lists 9 locations in 7 states (Other, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06848231 about?
NCT06848231 is a clinical study titled "A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy". This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
What is the current status of trial NCT06848231?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2025-03-03. Estimated completion is 2026-12-31.
What conditions does trial NCT06848231 study?
This clinical trial studies the following conditions: Multiple System Atrophy.
What interventions are being tested in trial NCT06848231?
The interventions under investigation include: Placebo (DRUG), YA-101 (DRUG).
Who is sponsoring clinical trial NCT06848231?
This trial is sponsored by Yoda Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06848231 being conducted?
This trial has 9 study locations across California, Massachusetts, Minnesota, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06848231's enrollment target sits among peer trials
75 15th of 30 higher than 16 of 30 other Multiple System Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple System Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
RECRUITING · Phase 2
-
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
RECRUITING · Phase 2
-
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
RECRUITING · Phase 2
-
A Study of Lu AF82422 in Participants With Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI